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Heated (20 min at 70°C) amphotericin B-desoxycholate (hAMB-DOC) was further characterized, as was
another formulation obtained after centrifugation (60 min, 3000 3 g), hcAMB-DOC. Conventional AMB-DOC
consisted of individual micelles (approximately 4 nm in diameter) and threadlike aggregated micelles, as
revealed by cryo-transmission electron microscopy. For both hAMB-DOC and hcAMB-DOC, pleiomorphic
cobweb structures were observed with a mean particle size of approximately 300 nm as determined by laser
diffraction. The potent antifungal activity of AMB-DOC against Candida albicans is not reduced by heating.
Effective killing of C. albicans (>99.9% within 6 h) was obtained at 0.1 mg/liter with each of the AMB
formulations. For AMB-DOC, hAMB-DOC, and hcAMB-DOC, cation release (86Rb1) from C. albicans of
>50% was observed at 0.8, 0.4, and 0.4 mg/liter, respectively. After heating of AMB-DOC, toxicity was reduced
16-fold as determined by red blood cell (RBC) lysis. For AMB-DOC, hAMB-DOC, and hcAMB-DOC, hemolysis
of >50% was observed at 6.4, 102.4, and 102.4 mg/liter, respectively. In contrast, AMB-DOC and its derivates
showed similar toxicities in terms of cation release from RBC. For AMB-DOC, hAMB-DOC, and hcAMB-DOC,
cation release (86Rb1) of >50% was observed at 1.6, 0.8, and 0.8 mg/liter, respectively. In persistently
leukopenic mice with severe invasive candidiasis, higher dosages of both hAMB-DOC and hcAMB-DOC were
tolerated than those of conventional AMB-DOC (3 versus 0.8 mg/kg of body weight, respectively), resulting in
significantly improved therapeutic efficacy. In conclusion, this new approach of heating AMB-DOC may be of
great value for further optimizing the treatment of severe fungal infections.
As the overall prognosis for immunocompromised patients
with severe invasive fungal infections remains poor, there is an
urgent need for therapeutic advances. Amphotericin B-desoxy-
cholate (AMB-DOC) remains the therapy of choice for most
invasive fungal infections, but its use is significantly limited by
toxic side effects. Lipid formulations of AMB have been de-
veloped by the pharmaceutical industry, with the primary aim
to reduce AMB’s toxicity. It is now clear from a number of
clinical studies that the three industrially produced AMB-lipid
formulations (Abelcet, Amphocil/Amphotec, and AmBisome)
are substantially less toxic than AMB-DOC (3, 10). Studies
with animal models of invasive fungal infections have clearly
demonstrated that often high dosages of AMB-lipid formula-
tions are needed for treatment to be effective (5). Questions
regarding the optimal dosing and duration of treatment in
human patients are still unanswered for each of the AMB-lipid
formulations. Therefore, and also because treatment with
AMB-lipid formulations is very expensive, many patients with
severe invasive fungal infections are still undergoing aggressive
treatment with conventional AMB-DOC.
It was recently shown by others (1, 2, 8, 9) that when AMB-
DOC is heated for 20 min at 70°C (hAMB-DOC), its toxicity is
greatly reduced without any effect on its potent antifungal
activity. In different models of invasive fungal infections in
immunocompetent mice, viz., systemic candidiasis, cryptococ-
cal pneumonia, and cryptococcal meningoencephalitis, higher
dosages of hAMB-DOC were tolerated than those of conven-
tional AMB-DOC, resulting in significantly improved thera-
peutic efficacy. Although the results of these first studies are
very encouraging, there are still many questions which need to
be answered.
In the present study, hAMB-DOC was further characterized.
Ultrastructure and mean particle size were determined. The in
vitro toxicity and influence of storage temperature on in vitro
toxicity were investigated. Furthermore, studies on the in vitro
antifungal activity and therapeutic efficacy in a model of severe
invasive candidiasis in persistently leukopenic mice were per-
formed. Additionally, it was investigated whether the hAMB-
DOC formulation could be further improved by centrifuga-
tion (hcAMB-DOC), yielding a preparation with relatively
increased numbers of AMB aggregates.
MATERIALS AND METHODS
Materials. Dimethyl sulfoxide (DMSO) was from Janssen Chimica (Tilburg,
The Netherlands). 86RbCl (specific activity, 1.5 to 2.2 mCi/mg at the reference
date) was from Amersham Pharmacia Biotech UK Limited (Little Chalfont,
Buckinghamshire, United Kingdom). Methanol and NaHCO3 were from Merck
(Darmstadt, Germany). Cyclophosphamide and DOC were from Sigma (St.
Louis, Mo.). Sabouraud dextrose agar was from Unipath Ltd. (Basingstoke,
United Kingdom). AMB-DOC (Fungizone) and pure AMB were kindly pro-
vided by Bristol Myers-Squibb (Woerden, The Netherlands).
AMB-DOC and its derivates. Stock AMB-DOC was prepared by reconstitu-
tion of a vial of Fungizone (50 mg of AMB and 41 mg of DOC) with 10 ml of
sterile water for injection. Stock hAMB-DOC was prepared as described by
Gaboriau et al. (2). First, a stock of AMB-DOC was prepared as described
above. Subsequently, the vial was heated for 20 min at 70°C. Stock hcAMB-DOC
was prepared as follows. First, a stock of hAMB-DOC was prepared as described
above. Subsequently, the total volume (10 ml) of hAMB-DOC was centrifuged
(60 min at 3000 3 g), after which the supernatant was discarded and the pellet
was resuspended in 10 ml of 5% (wt/vol) dextrose in sterile water (5-DW) for
injection.
The AMB concentration of the stock of either AMB-DOC, hAMB-DOC, or
hcAMB-DOC was determined spectrophotometrically at 405 nm after dilution of
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the stock 300-, 400-, and 500-fold in DMSO-methanol (1/1, vol/vol). Calibration
standards of pure AMB in DMSO-methanol (1/1, vol/vol) were used, ranging
from 2 to 20 mg/liter. For each AMB formulation, complete monomerization of
AMB was obtained after dilution of the stock in DMSO-methanol (1/1, vol/vol),
as similar absorption spectra were obtained for AMB-DOC, hAMB-DOC,
hcAMB-DOC, and pure AMB at a concentration of 10 mg/liter. After determi-
nation of the AMB concentration of the stock (approximately 5 g/liter for both
AMB-DOC and hAMB-DOC and approximately 4.7 g/liter for hcAMB-DOC),
further dilutions were made in aqueous solution as indicated in the descriptions
of the various experiments.
Candida strain. Candida albicans ATCC 44858 was used in all of the experi-
ments and was stored at 280°C in Todd-Hewitt broth (Difco Laboratories,
Detroit, Mich.) containing 10% (vol/vol) glycerol.
RBC. Red blood cells (RBC) were obtained from male RP strain albino rats
(specific pathogen free, 18 to 25 weeks old, 185 to 225 g; Harlan CPB, Austerlitz,
The Netherlands).
Animals. Specific-pathogen-free, 14- to 20-week-old, female BALB/c mice
were obtained from Iffa Credo (L’Arbresle, France).
Characterization of AMB-DOC and its derivates. The appearance of AMB-
DOC and its derivates was examined by cryo-electron microscopy. A copper grid
(700 mesh, hexagonal pattern, 3 to 4 mm thick, no support film) was dipped in the
suspension of AMB-DOC or its derivates. After withdrawing the grid from the
suspension, the excess liquid was blotted away with filter paper, leaving aqueous
thin films spanning the 30-mm holes in the grid. By a guided drop, the specimen
was vitrified in melting ethane. These preparatory steps were carried out in a
fully automated preparation chamber with temperature and humidity control.
After vitrification the specimens were transferred under liquid nitrogen to a
Gatan cryoholder and mounted on a Philips CM12 microscope. Micrographs
from the vitrified specimens were taken at 2170°C using low-electron-dose
conditions.
The particle size distributions of hAMB-DOC and hcAMB-DOC were deter-
mined by laser diffraction (Mastersizer; Malvern Instruments Ltd., Malvern,
United Kingdom).
In vitro killing of C. albicans. The in vitro activities of AMB-DOC and its
derivates in terms of effective killing (.99.9%) of C. albicans at an inoculum of
1.3 3 107 CFU/liter during 6 h of incubation were determined in three separate
experiments as described previously (11, 12). Briefly, a log-phase culture of C.
albicans was prepared. C. albicans was exposed during 6 h of incubation on a
roller to twofold-increasing concentrations of AMB-DOC or its derivates (0.025
to 1.6 mg of AMB/liter) in Antibiotic Medium No. 3 or to DOC (1.3 mg/liter) in
Antibiotic Medium No. 3. During incubation the numbers of viable C. albicans
organisms were determined at 2-h intervals by making plate counts of 10-fold
serial dilutions of the washed specimen on Sabouraud dextrose agar.
Ion fluxes in C. albicans. Cation fluxes in yeast cells were measured in three
separate experiments as described by Juliano et al. (4), with minor adaptations.
C. albicans was loaded with 86Rb1 (86RbCl) by incubating 3.5 3 107 CFU of C.
albicans/ml with 10 mCi of 86Rb1/ml in buffer solution (0.02% [wt/vol] NaHCO3
in 5-DW) for 24 h at 37°C on a roller. C. albicans cells were washed in buffer
solution to remove unincorporated 86Rb1. For efflux experiments C. albicans
(3.5 3 106 CFU/ml) was incubated for 90 min on a roller at 37°C in buffer
solution alone (control), in DOC in buffer solution (84 mg/liter), or in twofold-
increasing concentrations of AMB-DOC or its derivates in buffer solution (0.05
to 102.4 mg of AMB/liter). C. albicans was pelleted by centrifugation, and the
supernatant was recovered by careful aspiration. Radioactivity counts of 86Rb1
in the pellet and supernatant were determined using a gamma counter (Minaxi
gamma 5000 series; Packard Instrument Co., Inc., Downers Grove, Ill.). The
efflux (E) of 86Rb1 was determined according to the following formula: cpmsup/
(cpmsup 1 cpmpellet), where cpm is counts per minute and sup is supernatant.
The percentage of 86Rb1 release was calculated according to the following
formula: (Eexp 2 Econtrol)/(Emax 2 Econtrol) 3 100, where Eexp is the efflux of
86Rb1 from C. albicans after exposure to AMB-DOC or its derivates and Emax
is maximum efflux.
Ion fluxes in RBC. Cation fluxes in RBC were measured in three separate
experiments as described by Juliano et al. (4), with minor adaptations. Fresh,
washed RBC were loaded with 86Rb1 by incubating 100% (vol/vol) RBC with
100 mCi of 86Rb1/ml in buffer solution for 3 h at 37°C on a roller. RBC were
washed in buffer solution to remove unincorporated 86Rb1. For efflux experi-
ments, RBC (2%, vol/vol) were incubated for 60 min on a roller at 20°C in buffer
solution alone (control), in DOC in buffer solution (84 mg/liter), or in twofold-
increasing concentrations of AMB-DOC or its derivates in buffer solution (0.05
to 102.4 mg of AMB/liter). RBC were pelleted by centrifugation, and the super-
natant was recovered by careful aspiration. Radioactivity counts of 86Rb1 in the
pellet and supernatant and the 86Rb1 release were determined as described
above.
Hemolysis from RBC. Hemolysis from RBC was measured in three separate
experiments as described by Mehta et al. (7), with minor adaptations. Washed
RBC (2%, vol/vol) were incubated for 6 h on a roller with twofold-increasing
concentrations of AMB-DOC or its derivates in buffer solution (12.8 to 102.4 mg
of AMB/liter), in DOC in buffer solution (84 mg/liter), in buffer solution alone
(control), or in deionized water for 100% lysis. RBC were pelleted by centrifu-
gation, and released hemoglobin in the supernatant was determined by its ab-
sorbance at 580 nm. The percentage of hemolysis was calculated according to the
following formula: (Aexp 2 Acontrol)/(A100% 2 Acontrol) 3 100, in which A is the
absorbance at 580 nm. For both hAMB-DOC and hcAMB-DOC, hemolysis
experiments were performed immediately after preparation (time zero) and after
24 h, 48 h, or 8 days of storage at 14 and 280°C, respectively.
Determination of MTD in uninfected mice. Toxicity of AMB-DOC or its
derivates was measured in uninfected mice as described previously (12). Briefly,
mice (10 per group) were treated intravenously (i.v.) with a single dose of
AMB-DOC or its derivates. AMB dosages ranged from 0.1 to 1.0 mg/kg of body
weight in steps of 0.1 mg/kg and from 1 to 9 mg/kg in steps of 1 mg/kg. Mortality
was assessed immediately following injection of the preparation. Blood urea
nitrogen and serum creatinine, as parameters for renal toxicity, and aspartate
aminotransferase and alanine aminotransferase, as parameters for liver toxicity,
were determined by established methods in serum samples of mice sacrificed 24 h
or 14 days after termination of treatment. The maximum tolerated dosage
(MTD) was defined as the maximum dosage that did not result in death or a
.3-fold increase in the indices for renal and liver function compared to indices
of untreated mice.
Efficacies of AMB-DOC and its derivates in leukopenic mice infected with
C. albicans. Leukopenic mice were infected by C. albicans as previously described
(11, 12). AMB-DOC or its derivates were each administered i.v. as a single dose
either 6 or 16 h after C. albicans inoculation at dosages corresponding to their
MTDs. hAMB-DOC and hcAMB-DOC were also administered at a dosage
equivalent to the MTD of AMB-DOC. Controls were treated with 5-DW. Just
before treatment and 7 days after C. albicans inoculation, the surviving mice were
sacrificed. In the present study, only the number of viable C. albicans organisms
in the kidney was determined, as it was previously shown (11) that in this animal
model the kidney is the most severely infected organ. Survival rates of mice and
reduction in the numbers of viable C. albicans organisms in the kidneys were
used as parameters to assess the efficacy of treatment (10 mice per group).
Statistical analysis. Results of cation fluxes and hemolysis were expressed as
means 6 standard deviations (SD); sigmoidal fits (r2 . 0.99) of the dose re-
sponse curves were applied. Statistical evaluation of differences in the survival
rates (Kaplan-Meier plot) for mice with invasive candidiasis was performed by
the log rank test. This test examines the decrease in survival rates over time as
well as the final percentage of survival. Results of quantitative cultures in invasive
candidiasis were expressed as the geometric means 6 SD. Differences in viable
C. albicans counts between the various treatment groups were analyzed by using
the Mann-Whitney test. P values of #0.05 were considered significant in these
analyses.
RESULTS
Characterization of AMB-DOC and its derivates. AMB-
DOC consisted of individual micelles (approximately 4 nm in
diameter) and threadlike, aggregated micelles, as revealed by
cryo-transmission electron microscopy (Fig. 1A). For both
hAMB-DOC and hcAMB-DOC, pleiomorphic cobweb struc-
tures were observed (Fig. 1B and C, respectively), with a mean
particle size of approximately 300 nm as determined by laser
diffraction. The micellar (sub)structures were largely absent.
In vitro killing of C. albicans. For AMB-DOC and its deri-
vates, the minimal AMB concentrations required for killing
.99.9% of the initial C. albicans inoculum within 6 h of incu-
bation were determined. Both hAMB-DOC and hcAMB-DOC
were as effective as AMB-DOC, with effective killing obtained
at 0.1 mg/liter.
Ion fluxes in C. albicans. The effects of AMB-DOC and its
derivates on ion fluxes in C. albicans are shown in Fig. 2A.
Release of 86Rb1 after incubation in DOC alone never ex-
ceeded that of the controls (data not shown). For AMB-DOC,
hAMB-DOC, and hcAMB-DOC, 86Rb1 release of $50% was
observed at 0.8, 0.4, and 0.4 mg/liter, respectively.
Ion fluxes in RBC. The effects of AMB-DOC and its deri-
vates on ion fluxes in RBC are shown in Fig. 2B. Release of
86Rb1 after incubation in DOC alone never exceeded that of
the controls (data not shown). For AMB-DOC, hAMB-DOC,
and hcAMB-DOC, 86Rb1 release of $50% was observed at
1.6, 0.8, and 0.8 mg/liter, respectively.
Hemolysis of RBC. The effects of AMB-DOC and its deri-
vates on hemolysis of RBC are shown in Fig. 2B. Hemolysis
after incubation in DOC alone never exceeded that of the
controls (data not shown). After heating of AMB-DOC, tox-
icity was reduced 16-fold. For AMB-DOC, hAMB-DOC, and
VOL. 44, 2000 HEATED AMB: TOXICITY AND ANTIFUNGAL EFFICACY 1599
hcAMB-DOC, hemolysis of $50% was observed at 6.4, 102.4,
and 102.4 mg/liter, respectively.
Toxicity in terms of hemolysis of RBC remained low for
hAMB-DOC when stored at 280°C for up to 8 days. In con-
trast, toxicity of hAMB-DOC slowly increased during 8 days of
storage at 4°C, indicating that hAMB-DOC is unstable at 4°C.
hcAMB-DOC remained stable for 8 days at either 4 or 280°C.
MTD in uninfected mice. The MTDs of AMB-DOC and
derivates that were determined 24 h after single-dose treat-
ment are presented in Table 1. Similar results were observed
14 days after treatment (data not shown). For AMB-DOC the
MTD was 0.8 mg/kg, restricted by mortality after further in-
crease of the dose. For both hAMB-DOC and hcAMB-DOC
the MTD was 3 mg/kg; further increase of the dose resulted in
impaired liver function, whereas mortality of mice was ob-
served at dosages above 7 mg/kg.
Efficacies of AMB-DOC and its derivates in leukopenic mice
infected with C. albicans. The effects of early or delayed treat-
ment with AMB-DOC and its derivates on the survival of
leukopenic mice and growth of C. albicans in the kidney are
presented in Fig. 3 and Table 2. By increasing the delay be-
tween C. albicans inoculation and the time of treatment, the
efficacy of treatment in relation to the severity of infection
could be investigated. This was reflected in the number of
C. albicans CFU in the kidney at the time of treatment (Table
2). Placebo-treated mice die within 3 days of C. albicans inoc-
ulation. AMB-DOC administered i.v. as a single dose of the
MTD, 0.8 mg/kg, 6 h after C. albicans inoculation was only
partially effective; all mice survived up to 7 days after fungal
inoculation (P # 0.001 versus controls) (Fig. 3A). However,
numbers of viable C. albicans organisms in the kidney were
higher than at the time of treatment (Table 2). Similar results
were obtained after treatment with either hAMB-DOC or
hcAMB-DOC at 0.8 mg/kg (Fig. 3A and Table 2). Both
hAMB-DOC and hcAMB-DOC were more effective than
AMB-DOC at 3 mg/kg: 100% survival (P # 0.001 versus con-
trols) and significant reduction (P # 0.001) of the numbers of
viable C. albicans organisms in the kidney 7 days after inocu-
lation, compared to the time of treatment. Three of 10 mice
even had culture-negative kidneys after hAMB-DOC treat-
ment (Fig. 3A and Table 2). When treatment was delayed to
16 h after inoculation, AMB-DOC at 0.1 mg/kg, being the
MTD in these severely infected mice, resulted in only a slight
increase in survival rates (P # 0.05) compared to the controls
(Fig. 3B). A sixfold higher dose of hAMB-DOC or hcAMB-
DOC (0.6 mg/kg) was tolerated by these infected mice. At this
dose, treatment with either hAMB-DOC or hcAMB-DOC re-
sulted in significantly prolonged survival of mice compared to
FIG. 1. Cryo-transmission electron micrographs of small threadlike micelles
of AMB-DOC (arrows) (A), pleiomorphic cobweb structures of hAMB-DOC
(arrow) (B), and hcAMB-DOC, which has an appearance similar to that of
hAMB-DOC (arrow) (C). Regions of higher density near hole edges indicate
thicker ice. Bars 5 50 nm (A and C) and 60 nm (B).
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controls (P # 0.001) and compared to AMB-DOC treatment
at 0.1 mg/kg (P # 0.001). Survival after hAMB-DOC treatment
was more prolonged than after hcAMB-DOC treatment (P #
0.05) (Fig. 3B). For both derivates, numbers of viable C. albi-
cans organisms in the kidney were higher than at the time of
treatment (Table 2).
DISCUSSION
In the present study, hAMB-DOC was prepared by heating
(20 min, 70°C) a stock of conventional AMB-DOC (5 g/liter),
suspended in the original vial according to the manufactur-
er’s instructions. In a previous study on hAMB-DOC (2), the
stock AMB-DOC was first diluted to 92 mg/liter (1024 M)
before heating. In the present study, spectroscopic measure-
ments were performed for both conventional AMB-DOC and
hAMB-DOC after dilution of the stock in aqueous solution
(5-DW) to a concentration of 10 mg/liter. Absorption spectra
were similar to those described previously by Gaboriau et al.
(2), showing an absorption maximum at 327 nm for conven-
tional AMB-DOC and at 322 nm for hAMB-DOC (data not
shown). Therefore, it was concluded that hAMB-DOC could
FIG. 2. (A) Effects of AMB-DOC and its derivates on ion fluxes in yeast cells
(C. albicans). The release of 86Rb1 caused by various concentrations of AMB-
DOC (F), hAMB-DOC (), and hcAMB-DOC () was measured as described
in Materials and Methods. Data points are means of triplicate determinations.
(B) Effects of AMB-DOC and its derivates on ion fluxes (closed symbols) and
hemolysis (open symbols) of erythrocytes. The release of 86Rb1 and the hemo-
lysis induced by various concentrations of AMB-DOC (F and E), hAMB-DOC
( and ), and hcAMB-DOC ( and ) were determined as described in
Materials and Methods. Data points are means of triplicate determinations.
FIG. 3. Effect of early (A) or delayed (B) treatment with AMB-DOC or its
derivates on survival rates of persistently leukopenic mice with severe invasive
candidiasis (Kaplan-Meier plot). Leukopenic mice were inoculated i.v. at time
zero with 3 3 104 CFU of C. albicans. (A) Groups of 10 animals each were
treated i.v. 6 h after C. albicans inoculation with a single dose of AMB-DOC (F),
hAMB-DOC (), or hcAMB-DOC () at 0.8 mg of AMB/kg. (B) Mice were
treated 16 h after C. albicans inoculation with a single dose of AMB-DOC (F)
at 0.1 mg of AMB/kg or with hAMB-DOC () or hcAMB-DOC (), each at 0.6
mg of AMB/kg. Controls were treated with placebo (5-DW) ( n ). #, P # 0.05
versus placebo-treated mice; p, P # 0.001 versus placebo-treated mice.
TABLE 1. MTDs of AMB-DOC, hAMB-DOC, and
hcAMB-DOC in uninfected micea
Parameter for toxicityb
MTD (mg of AMB/kg)
AMB-DOC hAMB-DOC hcAMB-DOC
Death after treatment 0.8 7 7
Impaired renal function .0.8 5 5
Impaired liver function .0.8 3 3
a Mice were treated i.v. with a single dose. AMB dosages ranged from 0.1 to
1.0 mg/kg in steps of 0.1 mg/kg and from 1 to 9 mg/kg in steps of 1 mg/kg.
b Toxicity was determined as causing death after treatment or .3-fold in-
creases in the indices for renal function (blood urea nitrogen and serum creat-
inine) and liver function (aspartate aminotransferase and alanine aminotrans-
ferase) compared with those for untreated mice determined 24 h after treatment.
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be adequately prepared by heating the original vial with stock
AMB-DOC.
With respect to the particle size measurements of hAMB-
DOC, it should be noted that because of the cobweb-like
structure of the aggregates, the particle size could not be de-
termined exactly. All of the methods for particle size measure-
ments that are presently available are very accurate for per-
fectly round spheres, such as latex beads. Therefore, the results
that were obtained in the present study should be interpreted
with caution. It was clearly shown in the present study that
hAMB-DOC consists of a homogenous suspension of aggre-
gates with a mean particle size of about 300 nm. Only a very
small fraction of the suspension (less than 5%) consists of
much larger aggregates (particle sizes of 10 to 30 mm). For
hcAMB-DOC a similar particle size distribution was observed,
except that the particle size of the large aggregates ranged
from 10 to 100 mm.
In the present study, it was demonstrated by measuring both
cation release and viability of C. albicans that the potent anti-
fungal activity of AMB-DOC is not reduced by heating,
thereby confirming previous results (2) for which a different
experimental method was used. With respect to the toxicity in
vitro, it was shown that after heating of AMB-DOC, toxicity is
greatly reduced as determined by RBC lysis, which is in accor-
dance with previous results (2). In contrast, AMB-DOC and its
derivates showed similar toxicity in terms of cation release
from RBC. Gaboriau et al. (2) reported only a slight decrease
(threefold) in permeabilizing activity (K1 release from RBC)
after heating of AMB-DOC. As also discussed by Gaboriau et
al. (2), these two distinct mechanisms of action of AMB (per-
meabilizing effects and lytic effects) are yet not clearly eluci-
dated; therefore, the results cannot readily be explained. In our
opinion, the in vitro toxicity of hAMB-DOC needs to be fur-
ther investigated, focusing on other cell types and cell func-
tions.
With respect to the in vivo toxicity, there is a striking differ-
ence between conventional AMB-DOC and its derivates. For
conventional AMB-DOC, death was the dose-limiting event.
At dosages above the MTD (0.8 mg/kg), immediate death of
mice was observed, whereas no liver or renal toxicity was ob-
served at the MTD. For both hAMB-DOC and hcAMB-DOC,
immediate death was observed at dosages almost 10-fold
higher (.7 mg/kg). However, liver toxicity was observed at
much lower dosages (.3 mg/kg). Apparently, if treated with
hAMB-DOC or hcAMB-DOC, mice are protected from the
acute toxic effects seen with conventional AMB-DOC. The
observed liver toxicity might be the result of increased AMB
concentrations in the liver after administration of hAMB-DOC
or hcAMB-DOC. The biodistribution in mice of AMB after
administration of hAMB-DOC or AMB-DOC is presently un-
der investigation. Next to organ distribution, it is important to
further determine the cellular distribution of AMB, e.g., in the
liver. It is assumed that the particles in hAMB-DOC will be
primarily cleared from the circulation by the cells of the mono-
nuclear phagocyte system in liver and spleen. It is important
to investigate whether this might result in toxicity towards
liver macrophages in terms of impaired phagocytic functions
(13). It is also conceivable that during circulation in the
blood, AMB is transferred from hAMB-DOC to lipopro-
teins (14), by which specific transport of AMB to hepato-
cytes might occur.
Therapeutic efficacy of AMB-DOC and its derivates was
determined in a model of severe invasive candidiasis in persis-
tently leukopenic mice. Previously, improved therapeutic effi-
cacy of hAMB-DOC was demonstrated, compared to efficacy
of conventional AMB-DOC, in a model of invasive candidiasis
in immunocompetent mice (8). In that previous study, efficacy
of treatment was investigated in terms of survival of mice only;
quantitative cultures of viable C. albicans in the infected or-
gans were not presented. In the present study, the experimen-
tal setup was deliberately chosen, as we wanted to investigate
the potential of hAMB-DOC or hcAMB-DOC under very se-
vere circumstances. It was clearly demonstrated that for both
hAMB-DOC and hcAMB-DOC, higher dosages were toler-
ated than those for conventional AMB-DOC, resulting in sig-
nificantly improved therapeutic efficacy. Furthermore, it be-
came evident that the hAMB-DOC formulation is not further
improved by centrifugation.
In our opinion this new approach of heating AMB-DOC
may be of great value for further optimizing the treatment of
severe fungal infections. At present, the therapeutic efficacy of
hAMB-DOC is compared with that of conventional AMB-
TABLE 2. Effects of early or delayed treatment with AMB-DOC or its derivates on survival of leukopenic micea and
growth of C. albicans in the kidney
Time of
treatment Drug used









No. of mice with
sterile kidneys/no. of
surviving mice
6 h None (untreated) 3.3 6 0.2
Placebo (5-DW) 0
AMB-DOC 0.8 100 5.1 6 0.6 0/10
hAMB-DOC 0.8 100 5.0 6 0.6 0/10
hAMB-DOC 3 100 1.0 6 0.8d 3/10
hcAMB-DOC 0.8 100 5.2 6 0.6 0/10
hcAMB-DOC 3 100 1.3 6 0.5d 0/10
16 h None (untreated) 4.2 6 0.1
Placebo (5-DW) 0
AMB-DOC 0.1 0
hAMB-DOC 0.6 100 5.1 6 0.7 0/10
hcAMB-DOC 0.6 60 5.8 6 0.8 0/6
a Leukopenic mice were inoculated i.v. at time zero with 3 3 104 CFU of C. albicans; untreated mice died within 3 days after C. albicans inoculation.
b AMB-DOC, its derivates, and placebo were administered i.v.
c Each value is the geometric mean 6 SD.
d Significant decrease (P # 0.001) from number of CFU at the time of treatment.
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DOC in another clinically relevant model of severe invasive
fungal infection, viz., pulmonary aspergillosis in persistently
leukopenic rats (6).
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